Aurinia Pharmaceuticals Inc (AUPH)

[zzaatt]

To grant a Process Patent for a product which a company then makes significant investments in based on the duration and then, early on in the term, the USPO agrees to review the patent and change terms is, for lack of a better word, disgusting!

I totally agree with the above. There is an understanding that given the required expenditure of time and money to get the approval (based on patent preservation) from the FDA, it would violate simple notions of fairness and undermine the willingness (esp. of small, innovative companies) to committ to the effort involved.

I hope (and expect) that the review will be fully cognizant of this reasonable and customary assumption.